A-DASH (Asymmetric Dual-Signaling Hierarchical) BCMA x ISER-T

 

Category: Cell Therapy and Regenerative Medicine

Exhibitor: CAARLOGIC BIOMED CO. LTD.

Booth No: M534

 

Characteristic

 

Developed by Caarlogic Biomed, BCMA x ISER is a next-generation, modular hybrid-receptor framework conceptualized from our proprietary A-DASH (Asymmetric Dual-Signaling Hierarchical) CARxCCR technology. The flagship product integrates anti-BCMA CAR and ISER (Immune Synapse Enhancing Receptor) CCR targeting multiple myeloma, and functions like a "hybrid vehicle dual-power system" to deliver hierarchical, on-demand activation.
Our platform stands out with three core breakthroughs:
1. Hybrid Dual-Power Control: the hybrid system orchestrates balanced signaling with low baseline noise and ceiling maximum activation. The anti-BCMA CAR has two tandem alpaca anti-BCMA VHHs to eradicate BCMA-positive tumors while limiting off-target toxicity. Upon binding to BCMA, the 1st engine CAR triggers activation signal, and ISER remains quiet, minimizing clinical toxicities (e.g., CRS). However, if tumor cells downregulate BCMA to escape CAR surveillance, the 2nd engine, ISER, promptly activates and hunts down cancer cells.
2. Tumor Microenvironment (TME) Remodeling: ISER recognizes ligands expressed on immunosuppressive cells (e.g., MDSCs, CAFs), successfully remodeling the hostile TME.
3. Overcoming Manufacturing Barriers for High-Yield Production: Although the gene sequence of BCMA x ISER is significantly longer, Caarlogic has broken this limit. Using a in-house optimized 3rd-generation lentiviral packaging system, we have achieved robust viral yields to produce BCMA x ISER-T cells.
Our platform delivers a powerful trifecta of high efficacy, superior safety, and resistance to T-cell exhaustion, offering an industry-leading, scalable solution for next-generation cell therapy.

 

 

 

Back